Literature DB >> 26858357

Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia.

Yasuyuki Arai1, Tadakazu Kondo2, Hirohito Yamazaki3, Katsuto Takenaka4, Junichi Sugita5, Takeshi Kobayashi6, Yukiyasu Ozawa7, Naoyuki Uchida8, Koji Iwato9, Naoki Kobayashi10, Yoshiyuki Takahashi11, Ken Ishiyama12, Takahiro Fukuda13, Tatsuo Ichinohe14, Yoshiko Atsuta15, Takehiko Mori16, Takanori Teshima5.   

Abstract

Allogeneic bone marrow transplantation is an essential therapy for acquired aplastic anemia and prognosis has recently improved. However, engraftment failure and graft-versus-host disease are potential fatal complications. Various risk factors for poor prognosis have been identified, such as patient age and human-leukocyte antigen disparity, but the relationship between donor age and prognosis is still unknown. Therefore, we performed a cohort study to compare the prognosis of unrelated bone marrow transplantation from younger and older donors using the registry database in Japan. We evaluated 427 patients (age 16-72 years) with aplastic anemia who underwent bone marrow transplantation from younger (≤39 years, n=281) or older (≥40 years, n=146) unrelated donors. Overall survival of the older donor group was significantly inferior to that of the younger donor group (adjusted hazard ratio 1.64; 95% confidence interval 1.15-2.35; P<0.01). The incidence of fatal infection was significantly higher in the older donor group (13.7% vs. 7.5%; P=0.03). Primary engraftment failure and acute graft-versus-host disease were significantly more frequent in the older donor group (9.7% vs. 5.0%; adjusted hazard ratio 1.30; P=0.01, and 27.1% vs. 19.7%; adjusted hazard ratio 1.56; P=0.03, respectively). Acute graft-versus-host disease was related to a worse prognosis in the whole cohort. This study showed the inferiority of older donors in aplastic anemia; thus, donor age should be considered when multiple donors are available. A large-scale prospective study is warranted to establish a better donor selection algorithm for bone marrow transplantation in aplastic anemia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26858357      PMCID: PMC5004375          DOI: 10.3324/haematol.2015.139469

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  35 in total

1.  Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Authors:  J Mehta; L I Gordon; M S Tallman; J N Winter; A M Evens; A O Evens; O Frankfurt; S F Williams; D Grinblatt; L Kaminer; R Meagher; S Singhal
Journal:  Bone Marrow Transplant       Date:  2006-06-05       Impact factor: 5.483

Review 2.  The aging immune system: primer and prospectus.

Authors:  R A Miller
Journal:  Science       Date:  1996-07-05       Impact factor: 47.728

Review 3.  Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation.

Authors:  Simona Iacobelli
Journal:  Bone Marrow Transplant       Date:  2013-03       Impact factor: 5.483

4.  Risk factors for hypogammaglobulinemia after allo-SCT.

Authors:  Y Arai; K Yamashita; K Mizugishi; T Kondo; T Kitano; M Hishizawa; N Kadowaki; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

Review 5.  Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations.

Authors:  Serena Marotta; Simona Pagliuca; Antonio M Risitano
Journal:  Expert Rev Hematol       Date:  2014-10-21       Impact factor: 2.929

6.  Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia.

Authors:  Martin Stern; Jakob R Passweg; Anna Locasciulli; Gerard Socié; Hubert Schrezenmeier; Albert N Békássy; Monica Fuehrer; Jill Hows; Elisabeth T Korthof; Shaun McCann; André Tichelli; Nicholas C Zoumbos; Judith C W Marsh; Andrea Bacigalupo; Alois Gratwohl
Journal:  Transplantation       Date:  2006-07-27       Impact factor: 4.939

7.  The influence of CD4 T-cell subsets on control of CD4 T-cell-mediated graft-versus-host disease.

Authors:  Halima Moncrieffe; Mark Coles; Brigitta Stockinger
Journal:  Immunology       Date:  2008-05-20       Impact factor: 7.397

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

9.  Prediction of graft-versus-host disease in humans by donor gene-expression profiling.

Authors:  Chantal Baron; Roland Somogyi; Larry D Greller; Vincent Rineau; Peter Wilkinson; Carolyn R Cho; Mark J Cameron; David J Kelvin; Pierre Chagnon; Denis-Claude Roy; Lambert Busque; Rafick-Pierre Sékaly; Claude Perreault
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

10.  Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; Kazunari Aoki; June Takeda; Tadakazu Kondo; Tetsuya Eto; Shuichi Ota; Hisako Hashimoto; Takahiro Fukuda; Yukiyasu Ozawa; Yoshinobu Kanda; Chiaki Kato; Mineo Kurokawa; Koji Iwato; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Akiyoshi Takami
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

View more
  11 in total

1.  Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Authors:  Xia Qin; Yi-Ping Zhu; Cheng-Juan Luo; Ming Zhou; Ke Huang; Chun Chen; Wei-Ping Zhang; Yuan Sun; Rong-Mu Luo; Xiang-Feng Tang; Ting Yang; Xian-Min Song; Shao-Yan Hu; Zi-Min Sun; Jiong Hu; Shun-Qing Wang; Jing Chen
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

2.  Immune reconstitution in patients with acquired severe aplastic anemia after haploidentical stem cell transplantation.

Authors:  X-Y Pei; X-Y Zhao; L-P Xu; Y Wang; X-H Zhang; Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2017-08-14       Impact factor: 5.483

3.  Wild-type Kras expands and exhausts hematopoietic stem cells.

Authors:  Joshua P Sasine; Heather A Himburg; Christina M Termini; Martina Roos; Evelyn Tran; Liman Zhao; Jenny Kan; Michelle Li; Yurun Zhang; Stéphanie C de Barros; Dinesh S Rao; Christopher M Counter; John P Chute
Journal:  JCI Insight       Date:  2018-06-07

Review 4.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

5.  Assessing Early Supportive Care Needs among Son or Daughter Haploidentical Transplantation Donors.

Authors:  Nina D Wagner-Johnston; Susan M Hannum; JaAlah-Ai Heughan; Martha Abshire; Jennifer L Wolff; Kathryn Yarkony; Heather Symons; Richard J Jones; Sydney M Dy
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-08       Impact factor: 5.742

6.  [Risk-factors analysis of graft failure after allogeneic hematopoietic stem cell transplantation].

Authors:  Y Fei; X X Hu; Q Chen; A J Huang; H Cheng; X Ni; L Chen; L Gao; G S Tang; J Chen; W P Zhang; J M Yang; J M Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

7.  Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study.

Authors:  Lan-Ping Xu; Shun-Qing Wang; Yan-Ru Ma; Su-Jun Gao; Yi-Fei Cheng; Yuan-Yuan Zhang; Wen-Jian Mo; Xiao-Dong Mo; Yu-Ping Zhang; Chen-Hua Yan; Yu-Hong Chen; Ming Zhou; Yu Wang; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2019-09-02       Impact factor: 17.388

8.  A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies.

Authors:  Ida Marie Rundgren; Elisabeth Ersvær; Aymen Bushra Ahmed; Anita Ryningen; Øystein Bruserud
Journal:  Medicina (Kaunas)       Date:  2020-01-18       Impact factor: 2.430

Review 9.  Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization.

Authors:  Jaap Jan Boelens; Kinga K Hosszu; Stefan Nierkens
Journal:  Front Pediatr       Date:  2020-08-21       Impact factor: 3.418

10.  Long-term mid-onset dietary restriction rejuvenates hematopoietic stem cells and improves regeneration capacity of total bone marrow from aged mice.

Authors:  Si Tao; Yiting Wang; Jianying Wu; Ting Zeng; Hui Cui; Zhendong Tao; Lang Lei; Li Yu; Anwen Liu; Hua Wang; Liu Zhang; Duozhuang Tang
Journal:  Aging Cell       Date:  2020-09-15       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.